Boost Fertility's public identity rests on one documented regulatory event. FDA records linked by MedtechLedger show the Pleiades Device, submitted by My123Baby Medical Limited Dba Boost Fertility, received a Substantially Equivalent decision on October 30, 2026, under K262066. The manufacturer's own press release describes the product as a matchbox-sized, single-use sperm separation device intended to make sperm separation quick and easy to perform. Company materials place the device at the center of a planned treatment solution rather than as a standalone laboratory item. [1][3][2]

The applicant and the cleared record

The FDA record names My123Baby Medical Limited Dba Boost Fertility as the applicant for K262066, with Daniel Wilson listed as contact and a Munich, Germany address on the filing. The submission was received June 22, 2026, reviewed as a Traditional 510(k) without third-party review, and decided October 30, 2026. The device carries product code MQK, regulation number 884.6160, classification name Labware, Assisted Reproduction, device class 2, and Obstetrics/Gynecology as the review panel. A summary is noted as the statement or summary type. The filing address is a regulatory contact detail and does not establish a corporate headquarters. [1][4][5]

Independent indexes reproduce the same identifiers. FDA.report lists K262066 with the same applicant, product code, decision and dates, and Innolitics places the record under 21 CFR 884.6160 and product code MQK. Arca, citing FDA public records as of November 16, 2026, counts one 510(k) clearance for the company, the October 30, 2026 Pleiades Device. These are restatements of the same single filing, not separate clearances. [4][5][7]

What the Pleiades Device is documented to be

The manufacturer's press release, dated November 9, 2026, states that FDA cleared the Pleiades Device on Friday, October 30, 2026, through the 510(k) pathway, and describes it as a matchbox-sized, single-use sperm separation device that enables sperm separation to be performed quickly and easily. The same release quotes the device inventor and Chief Scientific Officer, Dr. Marion Vollmer, on planned usability feedback from healthcare professionals. The release does not state commercial availability, pricing, clinical performance or customer commitments. [3]

Company website material describes the Pleiades Device as the centerpiece of the Boost Fertility solution and credits Dr. Vollmer, working in Toronto, with developing a sperm preparation device designed for commercialization and home usage. LinkedIn company content refers to the Pleiades Device as part of a solution for healthcare providers. These are company characterizations of intended use and positioning, not independently verified performance claims. [2][8]

Company profile as published

The company website describes Boost Fertility as a medical device development and manufacturing company that has created a patented device to enable affordable and accessible infertility treatment. It lists Daniel Wilson as Chief Executive Officer, Dr. Marion Vollmer as Chief Technology Officer, and Patrick Welsh as Chief Revenue Officer, and states that the company was on track for FDA clearance in 2025, a target the October 2026 decision postdates. The site also states that shareholders have invested more than $3 million to date. [2][6]

LinkedIn company content describes Boost Fertility as a Munich, Bavaria medical device company with nine employees listed and 285 followers, and announces the Pleiades Device 510(k) clearance. The company's own pages direct couples, job seekers, partners and investors to separate sections. No parent company, ownership structure or corporate website domain is verified in the available records beyond the applicant name and the boostfertility.com and my123baby.com pages. [8][6][2]

How to read the collection counts

The linked-record collection for this company contains one 510(k) record, and the decision count for the full collection is one Substantially Equivalent decision. The record sample also contains one entry, the same K262066 filing, so the sample decision count of one matches the full collection rather than representing a subset. No premarket approval, de novo, recall or other pathway record appears in the collection. These counts describe the filings assembled as of November 20, 2026, and say nothing about sales, total portfolio breadth or safety performance. [1][7]